Get started
Author

Jose F. Ponte

Observed names: J. Ponte, JOSE F. PONTE, Jose F Ponte, Jose F. Ponte (1368942), Jose Ponte, Ponte, Jose
OpenAlex ID: A5112064423
Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
2003 · SAM THIAGALINGAM, KUANG‐HUNG CHENG, et al. · Annals of the New York Academy of Sciences · 700
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder
2006 · Hamid Mostafavi Abdolmaleky, Kuang-hung Cheng, et al. · Human Molecular Genetics · 458
PDF
Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates
2017 · Xiuxia Sun, Jose F. Ponte, et al. · Bioconjugate Chemistry · 279
Phase 1 dose‐escalation study of mirvetuximab soravtansine ( IMGN853 ), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors
2017 · Kathleen N. Moore, Hossein Borghaei, et al. · Cancer · 147
PDF
Differential DNA Hypermethylation of Critical Genes Mediates the Stage-Specific Tobacco Smoke-Induced Neoplastic Progression of Lung Cancer
2005 · Andrea L. Russo, Arunthathi Thiagalingam, et al. · Clinical Cancer Research · 145
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
2016 · Jose F. Ponte, Olga Ab, et al. · Neoplasia · 121
PDF
Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence
2002 · Sam Thiagalingam, Rebecca L. Foy, et al. · Current Opinion in Oncology · 109
A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer
2017 · Kathleen N Moore, Lainie P Martin, et al. · Future Oncology · 100
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody–Maytansinoid Conjugates
2016 · Jose F. Ponte, Xiuxia Sun, et al. · Bioconjugate Chemistry · 84
Loss of Heterozygosity Patterns Provide Fingerprints for Genetic Heterogeneity in Multistep Cancer Progression of Tobacco Smoke–Induced Non–Small Cell Lung Cancer
2005 · Hongjie Pan, Joseph Califano, et al. · Cancer Research · 59
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
2018 · Michael L. Miller, Manami Shizuka, et al. · Molecular Cancer Therapeutics · 57
PDF
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy
2020 · Jose F. Ponte, Leanne Lanieri, et al. · Molecular Cancer Therapeutics · 40
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing
2015 · Wayne C. Widdison, Jose F. Ponte, et al. · Bioconjugate Chemistry · 40
PDF
A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
2016 · Rajeeva Singh, Yulius Y. Setiady, et al. · Molecular Cancer Therapeutics · 38
Elucidation of Epigenetic Inactivation of SMAD8 in Cancer Using Targeted Expressed Gene Display
2004 · Kuang-hung Cheng, Jose F. Ponte, et al. · Cancer Research · 37
In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
2018 · Gary Altwerger, Elena Bonazzoli, et al. · Molecular Cancer Therapeutics · 35
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
2017 · Stuart W. Hicks, Katharine C. Lai, et al. · Neoplasia · 34
PDF
Enhancement of humoral and cellular immunity with an anti‐glucocorticoid‐induced tumour necrosis factor receptor monoclonal antibody
2010 · Jose F. Ponte, Paul Ponath, et al. · Immunology · 29
Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing
2019 · Juliet A. Costoplus, Karen H. Veale, et al. · ACS Medicinal Chemistry Letters · 24
Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.
2010 · M. Rosenzweig, J. Ponte, et al. · Journal of Clinical Oncology · 20
Abstract 2890: IMGN151 - A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression
2020 · Olga Ab, Laura M. Bartle, et al. · Cancer Research · 18
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
2018 · Christian Brand, Ahmad Sadique, et al. · EJNMMI Research · 17
PDF
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation
2009 · Fangming Gao, Jose F Ponte, et al. · Cancer Biology & Therapy · 17
PDF
Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs)
2019 · Katie E. Archer, Emily E. Reid, et al. · ACS Medicinal Chemistry Letters · 14
Works count: 89
Citation count: 2,694
H-index: 20
I10-index: 26
Year
Topic
Type